Astiban® in Schistosomiasis Mansoni: A Controlled Therapeutic Trial in a Nonendemic Area

View More View Less
  • Columbia School of Public Health and Administrative Medicine, and the New York City Health Department


One hundred and thirty-five patients suffering from schistosomiasis mansoni were divided into two groups at random. An experimental group of 69 patients was treated with a 20-ml course of a 10 percent solution of antimony dimercaptosodium succinate (TWSb/6 or Astiban®) over a 4- to 5-day period, while a control group of 66 patients was treated with an 80-ml course of 6.3 percent solution of antimony pyrocatechol sodium sulphonate (stibophen or Fuadin®) administered over a 6- to 7-week period.

The two drugs were moderately tolerated. Vomiting and rashes and/or pruritus were frequently encountered in the Astiban group while joint pains were a prominent feature during Fuadin therapy.

The cure rates obtained after a follow-up period of at least four months involving six stool examinations were 79.6 percent and 80.4 percent in the Astiban and Fuadin groups, respectively.

Under the existing conditions in New York City, Astiban has proved to be a potent schistosomicidal drug which can be applied with a reasonable degree of safety on an outpatient basis in mass therapy.

Author Notes

Assistant Professor, Department of Environmental Medicine and Community Health, State University of New York, N. Y.

Chief, Tropical Disease Division, New York City Health Department.

Physician in Charge, Washington Heights Tropical Disease Clinic, New York City.

Public Health Physician (Epidemiologist), New York City Health Department.